Smoothened variants explain the majority of drug resistance in basal cell carcinoma
about
Novel small molecules targeting ciliary transport of Smoothened and oncogenic Hedgehog pathway activation.CIViC databaseAn Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to VismodegibHedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulnessStructural basis of Smoothened regulation by its extracellular domainsDYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistanceDesign, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer.Crystal structure of a multi-domain human smoothened receptor in complex with a super stabilizing ligandEMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells.Smoothened Regulation: A Tale of Two Signals.Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics.Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Identification of Novel Smoothened Ligands Using Structure-Based Docking.Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions.Mutations in the Kinetochore Gene KNSTRN in Basal Cell CarcinomaSmoothened regulation in response to Hedgehog stimulation.Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome)I only have eye for ewe: the discovery of cyclopamine and development of Hedgehog pathway-targeting drugsPosaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.A Recurrent Mosaic Mutation in SMO, Encoding the Hedgehog Signal Transducer Smoothened, Is the Major Cause of Curry-Jones Syndrome.Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signalingClustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies.Solasonine, A Natural Glycoalkaloid Compound, Inhibits Gli-Mediated Transcriptional Activity.Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development.Molecular Control of Atypical Protein Kinase C: Tipping the Balance between Self-Renewal and DifferentiationDevelopment of thieno- and benzopyrimidinone inhibitors of the Hedgehog signaling pathway reveals PDE4-dependent and PDE4-independent mechanisms of action.INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma.The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.Emerging from their burrow: Hedgehog pathway inhibitors for cancer.Sonidegib for the treatment of advanced basal cell carcinoma.Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy.Development of anticancer agents targeting the Hedgehog signaling.AKT1 Activation is Obligatory for Spontaneous BCC Tumor Growth in a Murine Model that Mimics Some Features of Basal Cell Nevus Syndrome.Arl13b Promotes Gastric Tumorigenesis by Regulating Smo Trafficking and Activation of the Hedgehog Signaling Pathway.
P2860
Q27334489-E3180489-0D5C-4A8C-A532-5B8107B763C0Q27612411-B45D37AB-D5BE-4C57-A4B4-697866C16E8AQ27853239-353C65C6-1DCE-470D-B8C5-52F6EFFF9365Q28072902-963FFEBA-59DD-4596-8949-EC6844275472Q28277263-8F9F2537-5278-4490-8341-25F4ED5B7BC4Q28833786-9876BCC9-3F9C-4D29-BABB-58E553043131Q33687409-6EE6B2E1-E0CF-4211-8170-6104AF63F13CQ33721053-332EFA1F-EBF6-4890-A8C0-63504957DBA4Q33804808-976E38B1-2AC3-4A85-9A45-0682A9EB77DAQ34496658-C1E371B5-4F73-4DC0-A288-3D152DEB3271Q35756696-02889DE3-FA9B-4D71-B2A1-75BBD66D7814Q35868567-14344858-2B16-475C-9AA4-E1233507955DQ36094653-1426CF39-8152-423A-9859-06E5430805E9Q36207322-116F4140-6DB9-421A-9750-25F86B69B31DQ36234658-090778C6-921C-4C58-8617-B820E1DB7997Q36562921-962074AF-9D7C-4E0F-8DAD-90282A016C61Q36676046-1BE8A283-DE6A-4AFA-A145-1DC4E9AF9F68Q36803750-B20DF511-E30A-4765-8EEE-CE73407A51A2Q36819990-B9C35D26-B480-4D96-8546-72954B7D060FQ36869422-7657303C-4C17-4868-B3B3-C53F27A48DF2Q36917768-94EFE1B5-0A34-48F7-AB44-943EA4B98D6DQ36984038-A20B74C9-A5F0-4C86-95C9-8EA29EAAC03CQ37005200-961D6735-6211-4BFA-BAF9-C1718B3DB5D1Q37334087-69C33B34-5BF8-4D62-94D3-2A874FFD4553Q37482015-5B2C4D2E-C05C-4F46-B469-02155D6D3212Q37607838-DB5EF2A6-0F96-4605-9FD4-992B39EBE6AAQ37687028-84F0C9F5-AB89-40AC-BEEE-B2489CF56430Q38740268-153A538C-9B45-4A54-9593-EBAAE7D79663Q38748824-B9EA4004-F2A7-471E-831C-7DB0B4E74C7EQ38768033-4360EC18-D57B-45CC-AF32-1E39AC10673AQ38780502-34937ECA-CC94-4FB4-97E1-9B1D2C76ABBBQ38786405-3F7D8DF6-2210-4B7D-8E58-678706C568A3Q38811329-97C1E164-27A4-4B2B-8B6F-67D39D9D108BQ38820516-B45BA311-07D7-4755-A9AA-6AA23750E169Q38908981-C8A43DF7-1FC4-4925-BA24-106D0BF8F58DQ38930945-DA175CE4-D8A3-4FC0-A3A7-8F2D7D5726C2Q38935571-51A1B4D1-1CA0-4F5C-921A-1D475C9FE8F1Q39185473-B959BD9C-C838-4AA0-9F76-ADDC04C45BFEQ39623578-81D4112D-9891-4609-A63D-704B58AC98A8Q40161437-CF056D84-7879-495D-BAD6-589970499E9A
P2860
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
@ast
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
@en
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
@nl
type
label
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
@ast
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
@en
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
@nl
altLabel
Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma
@en
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
@en
prefLabel
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
@ast
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
@en
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
@nl
P2093
P2860
P3181
P1433
P1476
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
@en
P2093
Anne Lynn S Chang
Anthony E Oro
Catherine Yao
Geurim Kim
Jean Y Tang
Jiang R Li
Melika Rezaee
Mina S Ally
Ramon J Whitson
P2860
P304
P3181
P356
10.1016/J.CCELL.2015.02.002
P407
P577
2015-03-01T00:00:00Z